Here are five updates to know on orthopedic medtech company Enovis, as reported by Becker’s so far in 2025:
- The company recorded $565 million in net sales during the second quarter of 2025, an increase of 7% compared to the same quarter in 2024.
- Enovis expanded its device portfolio with the addition of the Manafuse Bone Growth Stimulator.
- Enovis experienced a decline in its stock prices following the release of its first quarter financial results.
- Damien McDonald took over as the company’s new CEO in May.
- The company is planning to build a new manufacturing facility in Austin, Texas, expecting to add 162 in the area.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
